Multiple sclerosis glatiramer acetate

Suhayl D-J. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 2(X)3 98 245-55. [Pg.85]

Glatiramer Acetate Mechanisms of Action in Multiple Sclerosis... [Pg.459]

Johnson BCP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Liska RP, Myers LW, Panitch HS, Rose JW, Schiffer TB, Vollmer T, Weiner LP, Wolinsky JS, Copolymer 1 Multiple Sclerosis Study Group (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurol 50 701—708. [Pg.601]

Johnson BCP, Brooker BR, Ford CC, Goodman A, Guamacci J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS, COP-1 Study Group (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients obseiwed for 6 year s. Mult Scler 6 255—266. [Pg.601]

Klran OA, Tslis AC, Kamholz JA, Gai bem JY, Lewis RA, Lisak RP (2001b) A prospective open-label ti eatment trial to compare the effect of IFN beta-la (Avonex), IFN beta-lb (Betaseron) and glatiramer acetate (Copaxone) on tire relapse rate in relapsing-remitting multiple sclerosis Results after 18 mondis of therapy. Mult Scler 7 349-353. [Pg.601]

Haas J (2003) Onset of chnical benefit of glatiramer acetate (Copaxone) acetate in 255 patients with relapsing remitting multiple sclerosis (RRMS). Neurol 60(suppl) P06-105. [Pg.600]

Multiple sclerosis Methylprednisolone, beta interferons, glatiramer acetate, antispasmodics, anticholinergics Weakness, paresthesias, vision, injection technique... [Pg.587]

Multiple sclerosis Beta interferons, glatiramer acetate, glucocorticoids, antispasmodics, amantadine, stimulants, immunosuppressants Number of exacerbations, self-injection technique, injection site reactions, amount of spasticity, amount of fatigue, CBC and infections (immunosuppressants), medication-specific adverse effects... [Pg.588]

Johnson KR Brooks BB, Ford CC, et al. Results of the long-term (eight year) prospective, open-label trial of glatiramer acetate for relapsing multiple sclerosis. Nemol Suppl 2002 58 R06.079. [Pg.1020]

Nicolau syndrome (embolia cutis medicamentosa) has been described in a 39-year-old woman with multiple sclerosis after subcutaneous treatment with glatiramer acetate for 2 years [55 ]. Continuation of treatment with glatiramer acetate at other injection sites was recommended, and further injections were well tolerated. The lesion healed within 10 weeks without any residual effects. [Pg.618]

Bains SN, Hsieh FH, Rensel MR, Radojicic C, Katz HT, Inamdar SR, Lang DM. Glatiramer acetate successful desensitization for treatment of multiple sclerosis. Ann Allergy Asthma Immunol 2010 104(4) 321-5. [Pg.643]

Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2004 (1)... [Pg.643]

In a case report, two patients with multiple sclerosis (MS) developed maculopapular exanthema related to the administration of glatiramer acetate (GA) which was thought to be due to delayed-type hypersensitivity reaction [25A]. [Pg.593]

Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol June 2013 73(6) 705-13. PubMed PMID 23686821. Epub 2013/05/21. eng. [Pg.600]

See also in sourсe #XX -- [ Pg.436 , Pg.437 , Pg.437 , Pg.439 ]

See also in sourсe #XX -- [ Pg.248 , Pg.419 , Pg.591 , Pg.592 , Pg.596 , Pg.597 , Pg.669 ]

See also in sourсe #XX -- [ Pg.248 , Pg.419 , Pg.591 , Pg.592 , Pg.596 , Pg.597 , Pg.669 ]

See also in sourсe #XX -- [ Pg.1012 , Pg.1014 , Pg.1015 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...